Literature DB >> 19578748

MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion.

Jingchun Gao1, Matthew J McConnell, Bin Yu, Jiannong Li, Justin M Balko, Esther P Black, Joseph O Johnson, Mark C Lloyd, Soner Altiok, Eric B Haura.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is aberrantly activated in human cancer including lung cancer and has been implicated in transformation, tumorigenicity, and metastasis. One putative downstream gene regulated by Stat3 is MUC1 which also has important roles in tumorigenesis. We determined if Stat3 regulates MUC1 in lung cancer cell lines and what function MUC1 plays in lung cancer cell biology. We examined MUC1 expression in non-small cell lung cancer (NSCLC) cell lines and found high levels of MUC1 protein expression associated with higher levels of tyrosine phosphorylated STAT3. STAT3 knockdown downregulated MUC1 expression whereas constitutive STAT3 expression increased MUC1 expression at mRNA and protein levels. MUC1 knockdown induced cellular apoptosis concomitant with reduced Bcl-XL and sensitized cells to cisplatin treatment. MUC1 knockdown inhibited tumor growth and metastasis in an orthotopic mouse model of lung cancer by activating apoptosis and inhibiting cell proliferation in vivo. These results demonstrate that constitutively activated STAT3 regulates expression of MUC1, which mediates lung cancer cell survival and metastasis in vitro and in vivo. MUC1 appears to be a cooperating oncoprotein with multiple oncogenic tyrosine kinase pathways and could be an effective target for the treatment of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19578748      PMCID: PMC4098131     

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  35 in total

1.  Stat3 regulates genes common to both wound healing and cancer.

Authors:  Daniel J Dauer; Bernadette Ferraro; Lanxi Song; Bin Yu; Linda Mora; Ralf Buettner; Steve Enkemann; Richard Jove; Eric B Haura
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

2.  MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90.

Authors:  J Ren; A Bharti; D Raina; W Chen; R Ahmad; D Kufe
Journal:  Oncogene       Date:  2006-01-05       Impact factor: 9.867

3.  Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.

Authors:  Eric B Haura; Zhong Zheng; Lanxi Song; Alan Cantor; Gerold Bepler
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

4.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

5.  Increased invasiveness of MUC1 and cDNA-transfected human gastric cancer MKN74 cells.

Authors:  T Suwa; Y Hinoda; Y Makiguchi; T Takahashi; F Itoh; M Adachi; M Hareyama; K Imai
Journal:  Int J Cancer       Date:  1998-05-04       Impact factor: 7.396

Review 6.  STAT signaling in the pathogenesis and treatment of cancer.

Authors:  D A Frank
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

7.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

Authors:  Jeffrey A Engelman; Pasi A Jänne; Craig Mermel; Joseph Pearlberg; Toru Mukohara; Christina Fleet; Karen Cichowski; Bruce E Johnson; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-24       Impact factor: 11.205

8.  Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis.

Authors:  Azzah Al Masri; Sandra J Gendler
Journal:  Oncogene       Date:  2005-09-01       Impact factor: 9.867

9.  Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression.

Authors:  F Guddo; A Giatromanolaki; C Patriarca; J Hilkens; C Reina; R M Alfano; A M Vignola; M I Koukourakis; M Gambacorta; G Pruneri; G Coggi; G Bonsignore
Journal:  Anticancer Res       Date:  1998 May-Jun       Impact factor: 2.480

10.  Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells.

Authors:  Jingchun Gao; Kenji Niwa; Wenshu Sun; Masao Takemura; Zenglin Lian; Kyoko Onogi; Mitsuru Seishima; Hideki Mori; Teruhiko Tamaya
Journal:  Cancer Sci       Date:  2004-11       Impact factor: 6.716

View more
  34 in total

1.  Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways.

Authors:  Mengying Yao; Weihong Zhang; Qingxian Zhang; Lihua Xing; Aiguo Xu; Qiuhong Liu; Bing Cui
Journal:  Lung       Date:  2011-10-01       Impact factor: 2.584

Review 2.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  Galectin-1 binds mucin in human trophoblast.

Authors:  Zanka Bojić-Trbojević; Milica Jovanović Krivokuća; Nikola Kolundžić; Miloš Petronijević; Svetlana Vrzić-Petronijević; Snežana Golubović; Ljiljana Vićovac
Journal:  Histochem Cell Biol       Date:  2014-05-23       Impact factor: 4.304

4.  IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines.

Authors:  Qinglin Liu; Gang Li; Ronghui Li; Jie Shen; Qiaowei He; Lin Deng; Cai Zhang; Jian Zhang
Journal:  J Neurooncol       Date:  2010-04-02       Impact factor: 4.130

5.  Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells.

Authors:  Carolyn M Klinge; Brandie N Radde; Yoannis Imbert-Fernandez; Yun Teng; Margarita M Ivanova; Sabra M Abner; Alexandra L Martin
Journal:  Mol Cancer Ther       Date:  2011-08-23       Impact factor: 6.261

6.  Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.

Authors:  Deepak Raina; Michio Kosugi; Rehan Ahmad; Govind Panchamoorthy; Hasan Rajabi; Maroof Alam; Takeshi Shimamura; Geoffrey I Shapiro; Jeffrey Supko; Surender Kharbanda; Donald Kufe
Journal:  Mol Cancer Ther       Date:  2011-03-18       Impact factor: 6.261

7.  Increased expression and aberrant localization of mucin 13 in metastatic colon cancer.

Authors:  Brij K Gupta; Diane M Maher; Mara C Ebeling; Vasudha Sundram; Michael D Koch; Douglas W Lynch; Teresa Bohlmeyer; Akira Watanabe; Hiroyuki Aburatani; Susan E Puumala; Meena Jaggi; Subhash C Chauhan
Journal:  J Histochem Cytochem       Date:  2012-08-20       Impact factor: 2.479

8.  HMGB1 enhances the protumoral activities of M2 macrophages by a RAGE-dependent mechanism.

Authors:  Armando Rojas; Fernando Delgado-López; Ramón Perez-Castro; Ileana Gonzalez; Jacqueline Romero; Israel Rojas; Paulina Araya; Carolina Añazco; Erik Morales; Jorge Llanos
Journal:  Tumour Biol       Date:  2015-10-06

9.  SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis.

Authors:  Susan Specht; Kumiko Isse; Isao Nozaki; John G Lunz; Anthony J Demetris
Journal:  Clin Exp Metastasis       Date:  2013-06-01       Impact factor: 5.150

10.  MUC1 downregulation inhibits non-small cell lung cancer progression in human cell lines.

Authors:  Tao Xu; Daowei Li; Hongmei Wang; Taohua Zheng; Guangqiang Wang; Ying Xin
Journal:  Exp Ther Med       Date:  2017-08-29       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.